MedTrace Logo

Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

NCT01229865 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2018-10-23

No results posted yet for this study

Summary

The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.

Conditions

  • Differential Thyroid Cancer

Interventions

DRUG

VB-111

Sponsors & Collaborators

  • Vascular Biogenics Ltd. operating as VBL Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2014-10-31
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01229865 on ClinicalTrials.gov